Skip to main content
Clinical Trials/2025-521718-24-00
2025-521718-24-00
Not yet recruiting
Phase 1

A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.

Tarchominskie Zaklady Farmaceutyczne Polfa S.A.1 site in 1 country56 target enrollmentStarted: July 15, 2025Last updated:

Overview

Phase
Phase 1
Status
Not yet recruiting
Sponsor
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Enrollment
56
Locations
1

Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

clinical department

Scientific

Tarchominskie Zaklady Farmaceutyczne Polfa S.A.

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Phase 1
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
2025-522921-37-00Gebro Pharma GmbH36
Completed
Phase 1
Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.
2024-513665-40-00Adamed Pharma S.A.62
Not yet recruiting
Phase 1
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2025-524217-89-00Vianex S.A.44
Recruiting
Phase 1
An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes
2025-523879-34-00Swedish Match North Europe AB72
Completed
Phase 1
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24
2024-510774-24-00Adamed Pharma S.A.30